cimetidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
histamine-H2-receptor antagonists, cimetidine derivatives	645	51481-61-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cimetidine tagamet tametin ulcedin ulcedine ulcerex ulcerfen cimetidine hydrochloride cimetidine HCl	A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Molecular weight: 252.34 Formula: C10H16N6S CLOGP: 0.38 LIPINSKI: 0 HAC: 6 HDO: 3 TPSA: 88.89 ALOGS: -3.16 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cimetidine
tagamet
tametin
ulcedin
ulcedine
ulcerex
ulcerfen
cimetidine hydrochloride
cimetidine HCl

A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.

Molecular weight: 252.34
Formula: C10H16N6S
CLOGP: 0.38
LIPINSKI: 0
HAC: 6
HDO: 3
TPSA: 88.89
ALOGS: -3.16
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.80	g	O
0.80	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	6.20 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	62 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	158.51 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.78 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 16, 1977	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urine abnormality	148.19	13.68	58	14317	6641	56271051
Urine leukocyte esterase positive	121.32	13.68	41	14334	3087	56274605
Body tinea	116.26	13.68	33	14342	1387	56276305
Inhibitory drug interaction	99.96	13.68	33	14342	2311	56275381
Infection susceptibility increased	94.40	13.68	33	14342	2750	56274942
Lymphocyte count decreased	88.09	13.68	66	14309	27873	56249819
Glucose tolerance impaired	75.76	13.68	34	14341	5471	56272221
Culture urine positive	72.61	13.68	29	14346	3499	56274193
Rheumatoid arthritis	69.97	13.68	8	14367	382596	55895096
Urine ketone body present	68.58	13.68	25	14350	2352	56275340
Blood urine present	61.40	13.68	40	14335	13515	56264177
Purpura	60.66	13.68	36	14339	10326	56267366
Hyperlipidaemia	59.80	13.68	44	14331	18065	56259627
Impaired quality of life	59.11	13.68	33	14342	8441	56269251
Chronic kidney disease	57.53	13.68	62	14313	41994	56235698
Poor quality sleep	56.08	13.68	42	14333	17713	56259979
Drug intolerance	55.43	13.68	3	14372	264815	56012877
Bone density decreased	51.39	13.68	35	14340	12725	56264967
Anaphylactoid reaction	49.35	13.68	22	14353	3484	56274208
Erythema	43.82	13.68	112	14263	155827	56121865
Joint swelling	42.18	13.68	11	14364	289789	55987903
Neutrophil count increased	41.99	13.68	33	14342	14932	56262760
Impaired work ability	40.60	13.68	32	14343	14540	56263152
Torsade de pointes	36.14	13.68	28	14347	12412	56265280
Oral herpes	35.32	13.68	36	14339	22854	56254838
Band sensation	33.51	13.68	11	14364	756	56276936
Drug ineffective	33.31	13.68	122	14253	918867	55358825
Skin disorder	32.88	13.68	37	14338	26272	56251420
Bacterial test positive	31.02	13.68	18	14357	4950	56272742
Specific gravity urine decreased	29.81	13.68	10	14365	735	56276957
Product use issue	29.15	13.68	6	14369	186035	56091657
Tri-iodothyronine free decreased	28.78	13.68	8	14367	311	56277381
Hypertension	28.74	13.68	131	14244	244147	56033545
Creatinine urine decreased	27.93	13.68	7	14368	181	56277511
Keratitis	27.60	13.68	14	14361	2953	56274739
Infusion site scar	27.25	13.68	8	14367	379	56277313
Red cell distribution width increased	27.08	13.68	21	14354	9319	56268373
Urticaria	26.29	13.68	89	14286	144587	56133105
Infusion site discomfort	25.99	13.68	10	14365	1092	56276600
Circulatory collapse	25.55	13.68	29	14346	20774	56256918
Therapeutic product effect decreased	25.47	13.68	6	14369	169446	56108246
Cataract	24.95	13.68	46	14329	51201	56226491
Arthropathy	24.88	13.68	10	14365	200265	56077427
Cellulitis	24.39	13.68	57	14318	74892	56202800
Product dose omission issue	24.20	13.68	11	14364	204742	56072950
Anxiety	23.76	13.68	105	14270	193067	56084625
Contraindicated product administered	23.64	13.68	9	14366	186277	56091415
Electrocardiogram T wave amplitude decreased	23.52	13.68	7	14368	348	56277344
Insomnia	23.38	13.68	104	14271	191756	56085936
Wound	22.75	13.68	4	14371	138800	56138892
Systemic lupus erythematosus	22.35	13.68	9	14366	180069	56097623
Death	22.11	13.68	156	14219	341270	55936422
Red blood cells urine positive	21.95	13.68	12	14363	2944	56274748
Red blood cell count decreased	21.91	13.68	36	14339	36581	56241111
Blood thyroid stimulating hormone increased	21.78	13.68	16	14359	6547	56271145
Peripheral swelling	21.58	13.68	17	14358	234709	56042983
Protein urine present	21.51	13.68	15	14360	5661	56272031
Basophil count increased	21.05	13.68	8	14367	845	56276847
Alanine aminotransferase increased	21.02	13.68	62	14313	93600	56184092
White blood cell count decreased	20.71	13.68	75	14300	125915	56151777
Urobilinogen urine increased	20.24	13.68	6	14369	294	56277398
Nitrite urine present	19.59	13.68	8	14367	1021	56276671
Infusion site rash	19.29	13.68	9	14366	1583	56276109
Palmar-plantar erythrodysaesthesia syndrome	18.80	13.68	25	14350	21040	56256652
Maternal exposure during pregnancy	18.36	13.68	13	14362	189540	56088152
Flushing	18.28	13.68	49	14326	70051	56207641
Chromaturia	18.21	13.68	21	14354	15304	56262388
Food interaction	18.19	13.68	7	14368	765	56276927
Myelosuppression	17.59	13.68	22	14353	17433	56260259
Monocyte count decreased	17.51	13.68	9	14366	1951	56275741
Pancreatitis acute	16.81	13.68	26	14349	25098	56252594
Infusion site warmth	16.70	13.68	8	14367	1492	56276200
White blood cells urine positive	16.60	13.68	12	14363	4790	56272902
Thyroid cyst	16.38	13.68	6	14369	572	56277120
Hepatic enzyme increased	16.27	13.68	12	14363	171372	56106320
Feeling hot	16.09	13.68	34	14341	41753	56235939
Intentional product use issue	16.07	13.68	3	14372	99730	56177962
Red cell distribution width decreased	16.02	13.68	8	14367	1631	56276061
Abdominal discomfort	15.98	13.68	29	14346	277245	56000447
Blood creatinine decreased	15.82	13.68	12	14363	5154	56272538
Lower respiratory tract infection	15.49	13.68	5	14370	114789	56162903
Anion gap decreased	15.40	13.68	5	14370	332	56277360
Glucose urine present	15.27	13.68	6	14369	693	56276999
Arthralgia	14.73	13.68	72	14303	501597	55776095
pH urine increased	14.71	13.68	5	14370	383	56277309
Immune thrombocytopenia	14.60	13.68	15	14360	9610	56268082
Eosinophil count increased	14.58	13.68	15	14360	9622	56268070
Drug exposure before pregnancy	14.37	13.68	6	14369	810	56276882
Herpes zoster	14.05	13.68	47	14328	75842	56201850
Haematocrit increased	13.97	13.68	8	14367	2146	56275546
Platelet count decreased	13.96	13.68	59	14316	106324	56171368
Lactic acidosis	13.89	13.68	29	14346	35317	56242375

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic kidney disease	35.61	15.68	39	5707	37936	31653662
Renal injury	21.91	15.68	17	5729	10648	31680950
Mucosal erosion	20.14	15.68	7	5739	810	31690788
Palmar-plantar erythrodysaesthesia syndrome	18.28	15.68	18	5728	15465	31676133
Peptic ulcer	18.10	15.68	9	5737	2567	31689031
Decreased appetite	16.48	15.68	63	5683	153154	31538444
Adulterated product	16.15	15.68	3	5743	25	31691573

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urine abnormality	157.14	13.23	62	16836	7776	70903770
Urine leukocyte esterase positive	117.96	13.23	41	16857	3604	70907942
Body tinea	114.79	13.23	32	16866	1351	70910195
Lymphocyte count decreased	93.94	13.23	80	16818	43459	70868087
Infection susceptibility increased	90.85	13.23	32	16866	2925	70908621
Inhibitory drug interaction	90.16	13.23	34	16864	3773	70907773
Urine ketone body present	75.77	13.23	29	16869	3350	70908196
Culture urine positive	69.41	13.23	29	16869	4208	70907338
Glucose tolerance impaired	68.09	13.23	33	16865	6773	70904773
Impaired quality of life	56.95	13.23	32	16866	8884	70902662
Poor quality sleep	55.75	13.23	43	16855	20306	70891240
Bone density decreased	54.47	13.23	34	16864	11440	70900106
Hyperlipidaemia	53.83	13.23	45	16853	23818	70887728
Blood urine present	51.07	13.23	40	16858	19313	70892233
Purpura	49.27	13.23	38	16860	17937	70893609
Erythema	44.53	13.23	126	16772	199437	70712109
Anaphylactoid reaction	43.33	13.23	22	16876	4985	70906561
Rheumatoid arthritis	40.24	13.23	10	16888	291795	70619751
Hypertension	37.79	13.23	155	16743	295878	70615668
Torsade de pointes	36.45	13.23	32	16866	18084	70893462
Impaired work ability	35.18	13.23	30	16868	16310	70895236
Oral herpes	33.93	13.23	35	16863	24151	70887395
Red cell distribution width increased	33.40	13.23	27	16871	13630	70897916
Urticaria	32.57	13.23	99	16799	162950	70748596
Off label use	32.19	13.23	82	16816	742978	70168568
Band sensation	30.94	13.23	10	16888	702	70910844
Palmar-plantar erythrodysaesthesia syndrome	30.76	13.23	37	16861	30210	70881336
Joint swelling	30.68	13.23	11	16887	253200	70658346
Infusion site scar	29.69	13.23	8	16890	297	70911249
Specific gravity urine decreased	29.31	13.23	10	16888	831	70910715
Flushing	29.10	13.23	62	16836	82110	70829436
Skin disorder	29.04	13.23	36	16862	30321	70881225
Alanine aminotransferase increased	28.94	13.23	89	16809	147391	70764155
Chronic kidney disease	28.83	13.23	52	16846	61005	70850541
Keratitis	28.19	13.23	15	16883	3742	70907804
Tri-iodothyronine free decreased	28.09	13.23	8	16890	365	70911181
Red blood cell count decreased	27.99	13.23	47	16851	52114	70859432
Infusion site discomfort	27.74	13.23	10	16888	977	70910569
Bacterial test positive	26.42	13.23	18	16880	7013	70904533
Haematocrit increased	25.66	13.23	14	16884	3668	70907878
Monocyte count decreased	25.27	13.23	13	16885	3026	70908520
Insomnia	24.64	13.23	110	16788	217696	70693850
Drug ineffective	24.04	13.23	129	16769	939623	69971923
Cataract	23.28	13.23	45	16853	55600	70855946
Neutrophil count increased	22.82	13.23	30	16868	26765	70884781
White blood cell count decreased	22.40	13.23	90	16808	170051	70741495
Peptic ulcer	22.36	13.23	15	16883	5698	70905848
Gastrooesophageal reflux disease	21.86	13.23	59	16839	90780	70820766
Creatinine urine decreased	21.81	13.23	6	16892	241	70911305
Therapeutic product effect decreased	21.53	13.23	4	16894	143014	70768532
Infusion site rash	21.43	13.23	9	16889	1323	70910223
Basophil count increased	21.16	13.23	9	16889	1364	70910182
Ventricular tachycardia	21.13	13.23	34	16864	36389	70875157
Secondary adrenocortical insufficiency	21.08	13.23	11	16887	2636	70908910
Mean cell haemoglobin increased	20.61	13.23	12	16886	3561	70907985
Red cell distribution width decreased	19.68	13.23	9	16889	1620	70909926
Protein urine present	19.64	13.23	17	16881	9423	70902123
Dyspepsia	19.60	13.23	56	16842	89021	70822525
Contusion	19.54	13.23	71	16827	127965	70783581
Blood thyroid stimulating hormone increased	19.14	13.23	16	16882	8463	70903083
Infusion site warmth	19.13	13.23	8	16890	1163	70910383
Nitrite urine present	19.12	13.23	8	16890	1164	70910382
Therapeutic product effect incomplete	18.82	13.23	3	16895	119879	70791667
Peripheral swelling	17.86	13.23	18	16880	236545	70675001
White blood cells urine positive	17.85	13.23	13	16885	5627	70905919
Drug exposure before pregnancy	17.40	13.23	6	16892	515	70911031
Product dose omission issue	17.05	13.23	16	16882	217452	70694094
Anxiety	17.01	13.23	100	16798	220230	70691316
Aspartate aminotransferase increased	16.57	13.23	67	16831	126911	70784635
Leukocyturia	16.56	13.23	8	16890	1629	70909917
Electrocardiogram T wave amplitude decreased	16.51	13.23	6	16892	600	70910946
Infusion site pruritus	16.40	13.23	10	16888	3227	70908319
Eosinophil count increased	16.10	13.23	19	16879	15203	70896343
Urobilinogen urine increased	15.87	13.23	6	16892	670	70910876
Platelet count decreased	15.82	13.23	84	16814	178138	70733408
Arthropathy	15.80	13.23	8	16890	150049	70761497
Product use issue	15.62	13.23	12	16886	179925	70731621
Red blood cells urine positive	15.24	13.23	11	16887	4698	70906848
Circulatory collapse	15.22	13.23	29	16869	35445	70876101
Blood alkaline phosphatase increased	15.08	13.23	39	16859	58482	70853064
Thyroid cyst	14.93	13.23	5	16893	392	70911154
Blood creatinine decreased	14.82	13.23	13	16885	7336	70904210
Mean cell haemoglobin concentration increased	14.76	13.23	6	16892	812	70910734
Mucosal erosion	14.72	13.23	8	16890	2081	70909465
pH urine increased	14.48	13.23	5	16893	431	70911115
Contraindicated product administered	14.44	13.23	7	16891	134605	70776941
Cellulitis	14.37	13.23	54	16844	98874	70812672
Wound	14.36	13.23	3	16895	98729	70812817
Gamma-glutamyltransferase increased	14.34	13.23	35	16863	50650	70860896
Product use in unapproved indication	14.32	13.23	17	16881	207461	70704085
Blood lactate dehydrogenase increased	14.20	13.23	28	16870	35099	70876447
Food interaction	13.78	13.23	7	16891	1586	70909960
Duodenal ulcer haemorrhage	13.78	13.23	12	16886	6706	70904840
Coronary artery disease	13.37	13.23	39	16859	62697	70848849
Hepatic function abnormal	13.29	13.23	41	16857	67955	70843591

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02BA01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists
ATC	A02BA51	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists
FDA MoA	N0000000151	Histamine H2 Receptor Antagonists
CHEBI has role	CHEBI:37961	H2 receptor antagonists
CHEBI has role	CHEBI:49201	anti-ulcer drugs
CHEBI has role	CHEBI:50183	P450 inhibitors
CHEBI has role	CHEBI:60809	adjuvants
MeSH PA	D000897	Anti-Ulcer Agents
MeSH PA	D065609	Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006635	Histamine H2 Antagonists
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D018377	Neurotransmitter Agents
FDA EPC	N0000175784	Histamine-2 Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Heartburn	indication	16331000
Upper gastrointestinal hemorrhage	indication	37372002
Duodenal ulcer disease	indication	51868009	DOID:1724
Zollinger-Ellison syndrome	indication	53132006	DOID:0050782
Multiple endocrine adenomas	indication	60549007
Indigestion	indication	162031009
Gastroesophageal reflux disease	indication	235595009	DOID:8534
Systemic mast cell disease	indication	397016004	DOID:349
Gastric ulcer	indication	397825006	DOID:10808
Upper GI Bleed Prevention	indication
Maintenance of Healing Duodenal Ulcer	indication
Pancreatic insufficiency	off-label use	37992001
Urticaria	off-label use	126485001
Prevention of Stress Ulcer	off-label use
NSAID-Induced Gastric Ulcer	off-label use
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Malignant tumor of stomach	contraindication	363349007	DOID:10534

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.83	acidic
pKa2	6.71	Basic
pKa3	0.0	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN	ANTAGONIST	Kd	6.14	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.16	PDSP
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	5.92	CHEMBL
Multidrug and toxin extrusion protein 2	Transporter	Q86VL8	S47A2_HUMAN	INHIBITOR	Ki	5.10	IUPHAR
Histamine H2 receptor	GPCR		HRH2_CAVPO		Kd	6.58	CHEMBL
Histamine H2 receptor	GPCR		HRH2_RAT	ANTAGONIST	Ki	5.90	IUPHAR

External reference:

ID	Source
4018845	VUID
N0000147147	NUI
D00295	KEGG_DRUG
70059-30-2	SECONDARY_CAS_RN
152402	RXNORM
4018844	VANDF
4018845	VANDF
C0008783	UMLSCUI
CHEBI:3699	CHEBI
CHEMBL30	ChEMBL_ID
CHEMBL1201051	ChEMBL_ID
DB00501	DRUGBANK_ID
D002927	MESH_DESCRIPTOR_UI
2756	PUBCHEM_CID
1231	IUPHAR_LIGAND_ID
3765	INN_ID
80061L1WGD	UNII
101	MMSL
2261	MMSL
4448	MMSL
4449	MMSL
6098	MMSL
d00140	MMSL
003415	NDDF
004987	NDDF
373541007	SNOMEDCT_US
83051006	SNOMEDCT_US
83532008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8192	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8192	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8204	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8204	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8305	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8305	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
Good Sense Heartburn Relief	HUMAN OTC DRUG LABEL	1	0113-0022	TABLET, FILM COATED	200 mg	ORAL	ANDA	16 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0649	SOLUTION	300 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0649	SOLUTION	300 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0121-1298	SOLUTION	400 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0121-1298	SOLUTION	400 mg	ORAL	ANDA	15 sections
cimetidineacid reducer	HUMAN OTC DRUG LABEL	1	0363-0022	TABLET, FILM COATED	200 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0053	TABLET, FILM COATED	200 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0317	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0372	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0541	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1282	TABLET	400 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	10544-626	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	10544-627	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-048	TABLET, FILM COATED	300 mg	ORAL	ANDA	17 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-265	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-372	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-531	TABLET	300 mg	ORAL	ANDA	14 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-532	TABLET	400 mg	ORAL	ANDA	14 sections
Good Neighbor Pharmacy Heartburn Relief	HUMAN OTC DRUG LABEL	1	24385-111	TABLET, FILM COATED	200 mg	ORAL	ANDA	16 sections
Acid Reducer	HUMAN OTC DRUG LABEL	1	30142-323	TABLET, FILM COATED	200 mg	ORAL	ANDA	16 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	33261-024	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	42291-217	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	42291-218	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Equate Cimetidine	HUMAN OTC DRUG LABEL	1	49035-820	TABLET, FILM COATED	200 mg	ORAL	ANDA	15 sections